NVS
Novartis AGNYSEHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
21.26
PEG
1.24
P/B
6.39
P/S
5.22
EV/EBITDA
14.02
DCF Value
$290.45
FCF Yield
5.7%
Div Yield
2.0%
Margins & Returns
Gross Margin
75.7%
Operating Margin
31.2%
Net Margin
24.9%
ROE
32.8%
ROA
23.1%
ROIC
16.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $13.33B | $2.41B | $1.25 |
| FY 2025 | $54.81B | $14.06B | $7.19 |
| Q3 2025 | $14.36B | $3.93B | $2.02 |
| Q2 2025 | $14.84B | $4.04B | $2.06 |
Analyst Ratings
View AllCompany Info
Sector
Healthcare
Industry
—
Country
CH
Exchange
NYSE
Beta
0.52
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.